NCT06538038 2026-03-27
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
Recruiting
Clinical Trials
13 trialsNCT07141563 2026-01-07
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
Bristol-Myers Squibb
Completed
NCT06883136 2025-03-19
Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
Qianfoshan Hospital
Enrolling by invitation
NCT04843007 2024-10-23
Alvopem® (Pemetrexed) Safety Assessment
NanoAlvand
Completed
NCT06607393 2024-09-23
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
Aetion, Inc.
Completed
NCT06585189 2024-09-05
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
Aetion, Inc.
Completed
NCT06532149 2024-08-09
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT06399926 2024-05-06
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
Xiangya Hospital of Central South University
Recruiting
NCT05273827 2024-01-05
Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium
Tianjin Medical University Cancer Institute and Hospital
Completed
NCT04465942 2021-08-23
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
European Lung Cancer Working Party
Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT00497770 2012-05-02
An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
Eli Lilly and Company
Completed
NCT00540241 2011-03-29
PERFORMANCE
Eli Lilly and Company
Completed